NEW YORK (GenomeWeb News) – MRIGlobal and Evogen today announced a five-year agreement to develop molecular diagnostic products targeting the in vitro and clinical molecular diagnostic markets.
Under the terms of the non-exclusive deal, MRIGlobal is providing product development services to Evogen, which was spun out of MRIGlobal in 2002. Services being provided include assay development, technology transfer, analytical and clinical studies, and commercialization support.
Financial terms of the agreement were not disclosed.
Evogen develops PCR-based molecular diagnostic systems and is based in Lenexa, Kan.
MRIGlobal, previously called Midwest Research Institute, is a not-for-profit research institute and development organization. Its Diagnostics Division provides assay development for menu expansion in in vitro and molecular diagnostics, validation and clinical testing, and other services. It is headquartered in Kansas City, Mo.